This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Schweizer, R. Articles by Ranke, M. B. Search for Related Content PubMed PubMed Citation Articles by Schweizer, R. Articles by Ranke, M. B. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Growth Disorders Related Collections Pediatric Endocrinology Calcium and Bone Metabolism Metabolism

Muscle Function Improves during Growth Hormone Therapy in Short Children Born Small for Gestational Age: Results of a Peripheral Quantitative Computed Tomography Study on Body Composition

Paediatric Endocrinology Section (R.S., D.D.M., M.B.R.), University Hospital for Children and Adolescents, D-72076 Tübingen, Germany; and Children’s Hospital (E.S.), University of Cologne, D-50924 Cologne, Germany

Address all correspondence and requests for reprints to: Roland Schweizer, M.D., Pediatric Endocrinology Section, University Hospital for Children and Adolescents, Hoppe Seyler Strasse 1, D-72076 Tuebingen, Germany. E-mail: Roland.Schweizer{at}med.uni-tuebingen.de.

Background: Short small for gestational age (SGA) children can be affected by a lack of muscle mass rather than fat mass. They also face a high risk of the metabolic syndrome developing after childhood. It is not known whether low muscle mass influences muscle function.

Aim: Our aim was to investigate muscle-fat distribution and muscle function before and during GH treatment in short SGA children.

Patients: A total of 34 prepubertal short SGA children (11 females, seven with Silver-Russell syndrome) were included in the study. Mean values were: age at GH start 7.3 yr; height SD score (SDS) –3.3; and birth weight SDS –2.7.

Methods: Investigations over 24 months on GH treatment (57 µg/kg·d) were performed. Body composition, including fat area and muscle area (MA), was assessed through peripheral quantitative computed tomography (XCT 2000; Stratec, Inc., Pforzheim, Germany). Maximal isometric grip force was performed with a Jamar dynamometer (Preston, Jackson, MI). Comparison with height-dependent reference values (SDS_Height) was calculated.

Results: MA SDS_Height at GH start was –1.8 and increased to –0.8 (P < 0.001) and –0.8, and fat area SDS_Height decreased from –0.6 to –2.0 (P < 0.001) and –1.5 after 12 and 24 months on GH. Maximal isometric grip force SDS_Height increased from –0.9 to 0.3 (P < 0.001) and 0.5. MA at start correlated negatively with height velocity (R = –0.54; P < 0.001) and MA SDS at start and -height SDS during the first year of GH treatment (R = –0.40; P < 0.001).

Conclusions: Short stature in SGA children is associated with low muscle mass and function. Supraphysiological GH doses led to a concomitant increment in height, muscle mass, and function, whereas fat mass decreased. Furthermore, body composition at GH start gives insight into GH responsiveness and the individual risk of metabolic syndrome.